一名患有肺动脉高压的婴儿从静脉注射曲前列尼尔过渡到口服司来帕格治疗。
Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
作者信息
Koo Rachel, Lo Jennifer, Bock Matthew J
机构信息
Department of Pediatrics,Loma Linda University Children's Health,Loma Linda, CA,USA.
Division of Pediatric Cardiology,Loma Linda University Children's Health,Loma Linda, CA,USA.
出版信息
Cardiol Young. 2019 Jun;29(6):849-851. doi: 10.1017/S1047951119001082.
Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.
司来帕格是一种经肠道给药的选择性前列环素 IP 受体激动剂，已被批准用于治疗成人肺动脉高压。关于其在儿童中的使用报道很少，在婴儿中则尚无相关报道。我们报告了首例婴儿（11.5 个月，8.6 千克）从静脉注射曲前列尼尔（40 纳克/千克/分钟）转换为口服司来帕格（每日两次，每次 400 微克）的病例，该婴儿反应良好且未出现不良反应。
Zotero 插件